DWTX Stock Analysis: Buy, Sell, or Hold?
DWTX - Dogwood Therapeutics, Inc. Common Stock
$1.71
0.07 (4.27%)
▲
5d:
+11.76%
30d:
+14.77%
90d:
+17.12%
BUY
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 12, 2026
7d
Get Alerted When DWTX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: DWTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: DWTX shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: DWTX is currently trading at $1.71, which is considered extended relative to its 30-day fair value range of $1.39 to $1.61.
Technical Outlook: Technically, DWTX is in a downtrend. The price is approaching resistance at $1.74. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: DWTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.00 (+718.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, DWTX is in a downtrend. The price is approaching resistance at $1.74. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 4.3% recently.
Market Sentiment: DWTX has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $14.00 (+718.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$1.39 -
$1.61
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
63.2%
All Signals
- BEARISH: Price extended above range (+6.2% above its trading range)
- BULLISH: Strong technical setup (60/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+4.3%)
- BULLISH: Trading 718.7% below Wall St target ($14.00)
Trading Range Analysis
30-Day Trading Range
$1.39 -
$1.61
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$1.35
Resistance Level
$1.74
Current Trend
Downtrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.62
Wall Street Target
$14.00
(+718.7%)
Share & Embed Analysis
Last updated: August 04, 2026 7:45 AM ET
Data refreshes hourly during market hours. Next update: 8:45 AM
Data refreshes hourly during market hours. Next update: 8:45 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is DWTX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$282 | 57 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$33 | 57 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$105 | 56 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
